
Shares of drugmaker AbbVie ABBV.N rise 2.7% to $185.3 premarket
AbbVie raises its 2025 profit forecast after better-than-expected sales of its newer immunology drugs Skyrizi and Rinvoq help it beat quarterly earnings expectations
Company expects its annual adjusted profit to be between $12.09 and $12.29 per share, up from its previous estimate of $11.99 to $12.19
ABBV earns adj. Q1 profit of $2.46 per share, compared with analysts' average expectation of $2.38
As of last close, ABBV had risen 1.5% YTD